2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T470,Of the 24 949 included patients, 1329 (5.3%) had a BSA assessment at index (963 had ≤10% BSA involvement; 366 had >10%). Most patients (n = 21 996 [88.2%]) were 18 years and older and female (n = 14 057 [56.3%]). The face was the most frequently affected area at index, impacting 5482 of 16 674 patients (32.9%) with reported location of vitiligo. Across BSA groups, 27% (6308 of 23 620 without BSA assessment) to 32% (310 of 963 with ≤10% BSA involvement) of patients did not receive treatment for vitiligo during follow-up. The most common treatments following index were topical and oral corticosteroids and topical calcineurin inhibitors/phosphodiesterase-4 inhibitors, with no substantial differences across BSA groups during follow-up. Topical treatments were prescribed more frequently to children and adolescents vs adults, while systemic treatments were prescribed more to adults. High variability across treatment sequences was observed. Median therapy duration ranged from 1.8 (95% CI, 1.6-2.1) months to 4.1 (95% CI, 3.7-4.4) months, for first and second lines of treatment depending on treatment type.31:Taca,Vitiligo is a chronic autoimmune disease characterized by loss of pigment in the skin, hair, or both, which can impact quality of life. To describe the demographic and clinical characteristics of patients with vitiligo and to characterize vitiligo treatment patterns, by vitiligo extent and age. This retrospective cohort study analyzed deidentified data from the linked Komodo Healthcare Map and OMNY Health Foundation databases. The linked databases capture health care and pharmacy claims and electronic health record data for patients with vitiligo receiving care in US dermatology practices and across all other settings. The index date was the date of first observed diagnosis of vitiligo during the index identification period (January 1, 2018, to August 31, 2023), allowing for 3 months or more of follow-up. Eligible patients were those with diagnosed vitiligo and 365 days or more of continuous health care plan enrollment (or eligibility proxy for patients with open claims) before index date. Patients missing age data or without any follow-up were excluded. Patients were stratified into cohorts by age and vitiligo percentage of body surface area (BSA) involvement (≤10%, >10%, and no BSA assessment) at index. The data analysis was conducted between April 2024 and August 2024. Baseline demographics, baseline clinical characteristics, and vitiligo treatment patterns following index date were described. Of the 24 949 included patients, 1329 (5.3%) had a BSA assessment at index (963 had ≤10% BSA involvement; 366 had >10%). Most patients (n = 21 996 [88.2%]) were 18 years and older and female (n = 14 057 [56.3%]). The face was the most frequently affected area at index, impacting 5482 of 16 674 patients (32.9%) with reported location of vitiligo. Across BSA groups, 27% (6308 of 23 620 without BSA assessment) to 32% (310 of 963 with ≤10% BSA involvement) of patients did not receive treatment for vitiligo during follow-up. The most common treatments following index were topical and oral corticosteroids and topical calcineurin inhibitors/phosphodiesterase-4 inhibitors, with no substantial differences across BSA groups during follow-up. Topical treatments were prescribed more frequently to children and adolescents vs adults, while systemic treatments were prescribed more to adults. High variability across treatment sequences was observed. Median therapy duration ranged from 1.8 (95% CI, 1.6-2.1) months to 4.1 (95% CI, 3.7-4.4) months, for first and second lines of treatment depending on treatment type. This cohort study reported treatment patterns in patients with vitiligo. A high proportion of patients with vitiligo did not receive treatment during follow-up, and therapy duration was relatively short.32:Tf08, Importance Vitiligo is a chronic autoimmune disease characterized by loss of pigment in the skin, hair, or both, which can impact quality of life. Objective To describe the demographic and clinical characteristics of patients with vitiligo and to characterize vitiligo treatment patterns, by vitiligo extent and age. Design, Setting, and Participants This retrospective cohort study analyzed deidentified data from the linked Komodo Healthcare Map and OMNY Health Foundation databases. The linked databases capture health care and pharmacy claims and electronic health record data for patients with vitiligo receiving care in US dermatology practices and across all other settings. The index date was the date of first observed diagnosis of vitiligo during the index identification period (January 1, 2018, to August 31, 2023), allowing for 3 months or more of follow-up. Eligible patients were those with diagnosed vitiligo and 365 days or more of continuous health care plan enrollment (or eligibility proxy for patients with open claims) before index date. Patients missing age data or without any follow-up were excluded. Patients were stratified into cohorts by age and vitiligo percentage of body surface area (BSA) involvement (≤10%, &gt;10%, and no BSA assessment) at index. The data analysis was conducted between April 2024 and August 2024. Main Outcomes and Measures Baseline demographics, baseline clinical characteristics, and vitiligo treatment patterns following index date were described. Results Of the 24 949 included patients, 1329 (5.3%) had a BSA assessment at index (963 had ≤10% BSA involvement; 366 had &gt;10%). Most patients (n = 21 996 [88.2%]) were 18 years and older and female (n = 14 057 [56.3%]). The face was the most frequently affected area at index, impacting 5482 of 16 674 patients (32.9%) with reported location of vitiligo. Across BSA groups, 27% (6308 of 23 620 without BSA assessment) to 32% (310 of 963 with ≤10% BSA involvement) of patients did not receive treatment for vitiligo during follow-up. The most common treatments following index were topical and oral corticosteroids and topical calcineurin inhibitors/phosphodiesterase-4 inhibitors, with no substantial differences across BSA groups during follow-up. Topical treatments were prescribed more frequently to children and adolescents vs adults, while systemic treatments were prescribed more to adults. High variability across treatment sequences was observed. Median therapy duration ranged from 1.8 (95% CI, 1.6-2.1) months to 4.1 (95% CI, 3.7-4.4) months, for first and second lines of treatment depending on treatment type. Conclusions and Relevance This cohort study reported treatment patterns in patients with vitiligo. A high proportion of patients with vitiligo did not receive treatment during follow-up, and therapy duration was relatively short. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Topical Calcineurin Inhibitor: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Topical Calcineurin Inhibitor (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Topical%20Calcineurin%20Inhibitor\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Topical Calcineurin Inhibitor\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Topical%20Calcineurin%20Inhibitor\"}]}}"}}]],["$","$L2f",null,{"title":"Topical Calcineurin Inhibitor: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Topical Calcineurin Inhibitor — concise summaries and practical next steps.","papers":[{"doi":"10.1001/jamadermatol.2026.0971","pmid":"42090147","title":"Clinical Characteristics and Treatment Patterns in Patients With Vitiligo","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-05-06T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.0971","source_score":26,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-11","doi":"10.1001/jamadermatol.2026.0971","days":"7","issn":"2168-6068","rank":"2","field":"Clinical Medicine","score":"26","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2026.0971","title":"Clinical Characteristics and Treatment Patterns in Patients With Vitiligo.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"42090147","conclusions":"","publication_date":"2026-05-06T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2026.0971","URL":"https://doi.org/10.1001/jamadermatol.2026.0971","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2848392/jamadermatology_adiri_2026_br_260005_1777558600.6133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Clinical Characteristics and Treatment Patterns in Patients With Vitiligo"],"author":[{"given":"Roni","family":"Adiri","sequence":"first","affiliation":[{"name":"Pfizer Pharmaceutical Israel LTD, Herzliya Pituach, Israel"}]},{"given":"Genevieve","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Kirkland, Quebec, Canada"}]},{"given":"Samantha K.","family":"Kurosky","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}]},{"given":"Mojgan","family":"Sadrarhami","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}]},{"given":"Griffith","family":"Bell","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}]},{"given":"Megan","family":"Fiasconaro","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ"}]},{"given":"Yun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Indiana University School of Medicine, Indianapolis"}]},{"given":"Nada M.","family":"Elbuluk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[{"name":"Palo Alto Foundation Medical Group, Sunnyvale, California"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henry Ford Hospital, Detroit, Michigan"}]}],"issued":{"date-parts":[[2026,5,6]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-05-06T15:31:32Z","timestamp":1778081492000,"date-parts":[[2026,5,6]]},"indexed":{"date-time":"2026-05-06T16:14:26Z","timestamp":1778084066965,"date-parts":[[2026,5,6]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2848392"}},"subtitle":[],"deposited":{"date-time":"2026-05-06T15:31:32Z","timestamp":1778081492000,"date-parts":[[2026,5,6]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2026,5,6]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1159/000506103","key":"dbr260005r1","year":"2020","issue":"6","author":"Bergqvist","volume":"236","first-page":"571","unstructured":null,"article-title":"Vitiligo: a review.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-021-00631-6","key":"dbr260005r2","year":"2021","issue":"6","author":"Ezzedine","volume":"22","first-page":"757","unstructured":null,"article-title":"Psychosocial effects of vitiligo: a systematic literature review.","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2013.927","key":"dbr260005r3","year":"2013","issue":"2","author":"Silverberg","volume":"149","first-page":"159","unstructured":null,"article-title":"Association between vitiligo extent and distribution and quality-of-life impairment.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19450","key":"dbr260005r4","year":"2023","issue":"11","author":"Seneschal","volume":"37","first-page":"2185","unstructured":null,"article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force—part 2: specific treatment recommendations.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2025.3512","key":"dbr260005r5","year":"2025","issue":"12","author":"Cheng","volume":"161","first-page":"1283","unstructured":null,"article-title":"Validating the use of ICD-10 codes for identifying vitiligo.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-023-00983-3","key":"dbr260005r6","year":"2023","issue":"9","author":"Rosmarin","volume":"13","first-page":"2079","unstructured":null,"article-title":"Real-world treatment patterns in patients with vitiligo in the United States.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-024-02875-0","key":"dbr260005r7","year":"2024","issue":"7","author":"Ramot","volume":"41","first-page":"2890","unstructured":null,"article-title":"Epidemiology and treatment patterns of patients with vitiligo: a real-world analysis.","journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.0021","key":"dbr260005r8","year":"2024","issue":"4","author":"Renert-Yuval","volume":"160","first-page":"453","unstructured":null,"article-title":"Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/jvc2.379","key":"dbr260005r9","year":"2024","issue":null,"author":"Lo","volume":"3","first-page":"401","unstructured":null,"article-title":"Adherence to treatment in dermatology: literature review.","journal-title":"JEADV Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.13377","key":"dbr260005r10","year":"2015","issue":"1","author":"Furue","volume":"172","first-page":"272","unstructured":null,"article-title":"Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by the Morisky Medication Adherence Scale-8.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.2147/PPA.S230921","key":"dbr260005r11","year":"2019","issue":null,"author":"Alsubeeh","volume":"13","first-page":"2029","unstructured":null,"article-title":"Treatment adherence among patients with five dermatological diseases and four treatment types — a cross-sectional study.","journal-title":"Patient Prefer Adherence","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":11,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,6]]},"references-count":11,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2026.0971","is_oa":true,"title":"Clinical Characteristics and Treatment Patterns in Patients With Vitiligo","updated":"2026-05-12T08:54:10+00:00","published_date":"2026-05-06","best_oa_location":{"url":"https://doi.org/10.1001/jamadermatol.2026.0971","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1001/jamadermatol.2026.0971"}}},"created_at":"2026-05-12T13:18:03.772Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"condition","value":"Vitiligo","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"generic","value":"ruxolitinib","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"modality","value":"Oral Corticosteroid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"modality","value":"Phosphodiesterase-4 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"modality","value":"Topical Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"sample_size","value":"n=24949","value_numeric":24949},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"warning","value":"AI-assisted drafting (GPT-4o) was used in producing the initial manuscript draft, which was subsequently edited by the authors.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"warning","value":"BSA documentation was available in only 5.3% of patients, so disease-severity subgroup analyses should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"warning","value":"This study was funded by Pfizer, and several authors are Pfizer employees; ruxolitinib (a Pfizer product) is mentioned as the only FDA-approved repigmentation therapy, which may introduce reporting or framing bias.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study described demographic/clinical characteristics and treatment patterns in 24,949 US patients with diagnosed vitiligo (2018–2023), stratified by age group and body surface area (BSA) involvement (≤10%, >10%, or no BSA recorded), using linked claims and EHR data.","key_result":"About 27–32% of patients received no treatment after diagnosis. The most common treatments were topical corticosteroids (TCS; 39% as first line), oral corticosteroids (OCS; 16%), and topical calcineurin inhibitors/PDE4 inhibitors (TCI/PDE4i; 16%). Median therapy duration was short: 1.8 months (95% CI, 1.6–2.1) for first-line and up to 4.1 months (95% CI, 3.7–4.4) for second-line treatment. Treatment sequences were highly variable, and only 5.3% of patients had BSA documented.","limitations":"- BSA was recorded in only 5.3% of patients, limiting the generalizability of disease-severity–stratified findings.\n- Claims data reflect dispensed medications, not actual use, so true treatment adherence and topical therapy duration may be overestimated or underestimated.\n- The cohort skewed toward commercially insured patients in dermatology settings, reducing generalizability to uninsured or primary-care–managed populations.","practice_takeaway":"Roughly one in three vitiligo patients received no treatment after diagnosis, and those who did tended to stop quickly — median first-line therapy lasted under 2 months. Clinicians should set clear expectations about treatment duration and monitor adherence, especially for topical regimens requiring frequent application."}},{"doi":"10.1016/j.jaad.2026.02.113","pmid":"41949508","title":"Guidelines of care for the management of atopic dermatitis in pediatric patients","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2026-04-07T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2026.02.113","source_score":103,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T17:34:05.456Z","updated_at":"2026-05-07T17:34:05.456Z","tags":[{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Adbry","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Cibinqo","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Dupixent","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Ebglyss","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Eucrisa","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Olumiant","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Opzelura","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Rinvoq","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Vtama","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"abrocitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"azathioprine","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"baricitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"crisaborole","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"cyclosporine","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"dupilumab","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"lebrikizumab","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"mycophenolate mofetil","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"nemolizumab","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"roflumilast","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"ruxolitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"tapinarof","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"tralokinumab","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"Conventional Immunosuppressant","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"PDE4 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"Phototherapy","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"Topical Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"warning","value":"Brand name for nemolizumab (Nemluvio) and lebrikizumab (Ebglyss) inclusion is based on known drug-brand mapping; verify current approvals for pediatric indications.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"warning","value":"Brand name for roflumilast cream (Zoryve) was not explicitly stated in the abstract; brand tag was omitted to avoid speculation.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"warning","value":"No total sample size is reported — this is a guideline/systematic review, not a single trial; sample_size tag was omitted.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"warning","value":"The DOI publication date (2026-04-07) is in the future relative to the 2014 AAD guidelines it updates, consistent with today's date of May 7, 2026.","value_numeric":null}],"summaries":{"what_studied":"A multidisciplinary AAD workgroup evaluated topical, phototherapy, and systemic treatments for atopic dermatitis (AD) in children and adolescents, using a systematic review and GRADE methodology to update the 2014 AAD guidelines.","key_result":"27 evidence-based recommendations were developed. Strong recommendations support moisturizers, topical corticosteroids, topical calcineurin inhibitors, crisaborole, roflumilast, ruxolitinib, tapinarof, dupilumab, tralokinumab, lebrikizumab, nemolizumab (with topical therapy), upadacitinib, abrocitinib, and baricitinib. Conditional recommendations favor bathing, bleach baths, wet dressings, phototherapy, methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine. Systemic corticosteroids are strongly recommended against.","limitations":"Most RCTs for AD therapies are short in duration, limiting conclusions about long-term efficacy and safety. Evidence is based on best available data at time of review only.","practice_takeaway":"Multiple biologic and JAK inhibitor options now carry strong recommendations for pediatric AD — clinicians should prioritize these over systemic corticosteroids, which are strongly discouraged. Conditional support exists for older immunosuppressants when newer agents are inaccessible."}},{"doi":"10.1016/j.cgh.2025.07.036","pmid":"41159991","title":"Isolated Esophageal Lichen Planus Effectively Treated With Topical Tacrolimus","journal_title":"Clinical Gastroenterology and Hepatology","journal_issn":"1542-3565","published_at":"2025-10-29T00:00:00.000Z","url":"https://doi.org/10.1016/j.cgh.2025.07.036","source_score":6,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-31T13:35:35.937Z","updated_at":"2026-05-31T13:35:35.937Z","tags":[{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"condition","value":"Esophageal Lichen Planus","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"generic","value":"tacrolimus","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"modality","value":"Topical Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"study_design","value":"Case Report or Case Series","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"warning","value":"Full text was not available; summary is based solely on the title, journal, and DOI metadata. Specific patient numbers, outcomes data, and study design could not be verified.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"warning","value":"Sex of patient(s) not determinable from available metadata; tag omitted.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.07.036","tag_type":"warning","value":"Study design labeled as 'Case Report or Case Series' based on the publication format typical for this type of report — confirmation from full text is recommended.","value_numeric":null}],"summaries":{"what_studied":"This report evaluated topical tacrolimus as a treatment for isolated esophageal lichen planus (ELP) — a rare condition without cutaneous or mucosal involvement — in patients who may be refractory or intolerant to standard therapies.","key_result":"Topical tacrolimus was effective in treating isolated esophageal lichen planus, based on the findings reported in this case-level publication.","limitations":"Limited generalizability given the likely small case series or case report format; no control group or comparative data; long-term outcomes and safety data are not established.","practice_takeaway":"For patients with isolated esophageal lichen planus, topical tacrolimus may be a viable therapeutic option worth considering, particularly when conventional treatments have failed or are not tolerated."}},{"doi":"10.1016/j.jaad.2022.08.068","pmid":"36623556","title":"Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapies","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2023-01-10T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2022.08.068","source_score":354,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2023-02-03","doi":"10.1016/j.jaad.2022.08.068","days":"30","issn":"0190-9622","rank":"2","field":"Clinical Medicine","score":"354","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jaad.2022.08.068","title":"Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapies.","journal":"Journal of the American Academy of Dermatology","methods":"","results":"","abstract":"These guidelines update the 2014 recommendations for management of atopic dermatitis in adults with topical therapies. A multidisciplinary workgroup employed best practices for guideline development, including a systematic review of the evidence and application of the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of the evidence and formulating and grading recommendations. The evidence on atopic dermatitis treatment supported strong recommendations for the use of nonprescription moisturizers, topical calcineurin inhibitors, topical corticosteroids, and topical PDE-4 and JAK inhibitors. Conditional recommendations are made for the use of bathing and wet wrap therapy and against the use of topical antimicrobials, antiseptics, and antihistamines.","keywords":["JAK inhibitor","antihistamines","antimicrobials","atopic dermatitis","bathing","calcineurin inhibitors","corticosteroids","emollients","topicals","wet wraps"],"pubmed_id":"36623556","conclusions":"","publication_date":"2023-01-10T00:00:00"},"crossref":{"DOI":"10.1016/j.jaad.2022.08.068","URL":"https://doi.org/10.1016/j.jaad.2022.08.068","ISSN":["0190-9622"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0190962223000567?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0190962223000567?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"128-129","type":"journal-article","issue":"1","score":1,"title":["Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapies"],"author":[{"given":"Robert","family":"Sidbury","sequence":"first","affiliation":[]},{"given":"Ali","family":"Alikhan","sequence":"additional","affiliation":[]},{"given":"Lionel","family":"Bercovitch","sequence":"additional","affiliation":[]},{"given":"David E.","family":"Cohen","sequence":"additional","affiliation":[]},{"given":"Jennifer M.","family":"Darr","sequence":"additional","affiliation":[]},{"given":"Aaron M.","family":"Drucker","sequence":"additional","affiliation":[]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[]},{"given":"Lindsy","family":"Frazer-Green","sequence":"additional","affiliation":[]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[]},{"given":"Kathryn","family":"Schwarzenberger","sequence":"additional","affiliation":[]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[]},{"given":"Anne Marie","family":"Singh","sequence":"additional","affiliation":[]},{"given":"Peggy A.","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Dawn M.R.","family":"Davis","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/100001934","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100001934","name":"American Academy of Dermatology","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2023,7]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"89","created":{"date-time":"2023-01-07T01:16:02Z","timestamp":1673054162000,"date-parts":[[2023,1,7]]},"indexed":{"date-time":"2025-08-27T16:01:29Z","timestamp":1756310489308,"date-parts":[[2025,8,27]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000,"date-parts":[[2023,7,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0190962223000567"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapies"},{"name":"journaltitle","label":"Journal Title","value":"Journal of the American Academy of Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jaad.2022.08.068"},{"name":"associatedlink","label":"CrossRef DOI link to the associated document","value":"https://doi.org/10.1016/j.jaad.2022.12.029"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2023 by the American Academy of Dermatology, Inc."}],"deposited":{"date-time":"2023-12-09T08:46:23Z","timestamp":1702111583000,"date-parts":[[2023,12,9]]},"issn-type":[{"type":"print","value":"0190-9622"}],"published":{"date-parts":[[2023,7]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/j.jaad.2014.03.023","key":"10.1016/j.jaad.2022.08.068_bib1","year":"2014","issue":"1","author":"Eichenfield","volume":"71","first-page":"116","unstructured":null,"article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0190962223000567"],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,7]]},"reference-count":1,"published-online":null,"references-count":1,"short-container-title":["Journal of the American Academy of Dermatology"],"is-referenced-by-count":10},"unpaywall":{"doi":"10.1016/j.jaad.2022.08.068","is_oa":false,"title":"Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapies","updated":"2025-05-22T18:42:22+00:00","published_date":"2023-01-07","best_oa_location":null}},"created_at":"2025-09-22T04:00:58.889Z","updated_at":"2025-09-22T14:20:55.574Z","tags":[{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"modality","value":"Bathing","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"modality","value":"Moisturizer","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"modality","value":"PDE-4 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"modality","value":"Topical Antihistamine","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"modality","value":"Topical Antimicrobial","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"modality","value":"Topical Antiseptic","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"modality","value":"Topical Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"modality","value":"Wet Wrap Therapy","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"study_design","value":"Guideline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"warning","value":"Design is a guideline based on a systematic review rather than a primary comparative study.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2022.08.068","tag_type":"warning","value":"Only summary-level details were available; no numeric effect sizes or graded certainty levels are provided in the text.","value_numeric":null}],"summaries":{"what_studied":"Updated guidelines for managing atopic dermatitis in adults using topical therapies, based on a systematic review and GRADE methodology to assess evidence and make recommendations.","key_result":"Strong recommendations were made for nonprescription moisturizers, topical calcineurin inhibitors, topical corticosteroids, and topical PDE-4 and JAK inhibitors; conditional recommendations were made for bathing and wet wrap therapy and against topical antimicrobials, antiseptics, and antihistamines.","practice_takeaway":"For adult atopic dermatitis, prioritize moisturizers and guideline-supported topicals (corticosteroids, calcineurin inhibitors, PDE-4 and JAK inhibitors); consider bathing and wet wraps selectively, and avoid topical antimicrobials, antiseptics, and antihistamines."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Topical Calcineurin Inhibitor"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Topical Calcineurin Inhibitor"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Topical Calcineurin Inhibitor"}}}]]

Papers